文献速递乳腺乳腺X线MRUS

导管原位癌主动监测患者的影像学变化与结局:七年随访研究

Imaging Changes and Outcomes of Patients Undergoing Active Monitoring for Ductal Carcinoma In Situ: Seven-Year Follow-up Study.
PubMed 文献 · Acad Radiol · 2024-01-05

本回顾性队列研究纳入2003至2022年单中心接受主动监测的39例导管原位癌患者,中位随访4.3年。64%(25/39)患者影像稳定且无进展;14例出现24项影像变化并接受活检,浸润癌总体阳性预测值为29%(7/24),新发肿块38%(3/8)和新发钙化33%(3/9)最高。

要点

  • 主动监测中64%(25/39)患者影像稳定且无进展,中位随访4.3年。
  • 新发肿块对浸润进展的阳性预测值为38%(3/8),新发钙化为33%(3/9)。
  • 影像变化总体阳性预测值为29%(7/24),非肿块强化为17%(1/6)。

核心结论

  • 在促使额外活检的影像变化中,新发肿块(38%)和新发钙化(33%)对浸润进展的阳性预测值最高;密切影像随访应作为导管原位癌监测患者的关键组成部分。

研究设计与样本

  • 七年随访回顾性IRB豁免队列研究,单学术机构2003至2022年诊断为导管原位癌并选择主动监测的患者39例,中位年龄58.4岁(IQR 51.1-69.6岁),中位随访4.3年(范围0.6-16.4年)。

关键影像表现/征象

  • 64%(25/39)患者影像稳定(范围0.6-16.4年)且主动监测期间无进展。
  • 其余14例(36%)出现24项影像发现,促使22次后续空心针活检(每人1-3次)和2次手术活检。

诊断标准与关键数值

  • 低风险导管原位癌定义为低或中级别且激素受体(雌激素和/或孕激素受体)阳性、年龄至少40岁的女性。
  • 进展定义为后续同侧浸润性乳腺癌诊断。
  • 浸润癌阳性预测值总体29%(7/24),肿块38%(3/8),钙化33%(3/9),非肿块强化17%(1/6),结构扭曲0%(0/1)。

临床应用与阅片要点

  • 作者认为密切影像随访应作为导管原位癌主动监测患者的关键组成部分。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To determine the imaging changes and their associated positive predictive value (PPV) for invasive breast cancer in women undergoing active monitoring for ductal carcinoma in situ (DCIS).

MATERIALS AND METHODS: In this seven-year follow-up retrospective IRB-exempted cohort study, we reviewed patients diagnosed with DCIS who elected active monitoring between 2003 and 2022 at a single academic institution. Imaging characteristics, histopathology at initial diagnosis, and subsequent follow-up were recorded. Low-risk DCIS was defined as low or intermediate grade and hormone receptor (HR) positive (estrogen and/or progesterone receptor positive) disease diagnosed in women at least 40 years of age. Progression was defined as subsequent ipsilateral invasive breast cancer diagnosis.

RESULTS: There were 39 patients with a median age of 58.4 years (IQR: 51.1-69.6 years) and a median follow-up of 4.3 years (range: 0.6-16.4 years). Nearly two thirds of patients (64%, 25/39) had stable imaging (range: 0.6-16.4 years) and remained progression-free during active monitoring. Among the remaining 14 patients (36%), there were 24 imaging findings which prompted 22 subsequent core needle biopsies (range: 1-3 biopsies per patient) and two surgical biopsies. The PPV of invasive cancer was 29% (7/24) overall and 38% (3/8) for masses, 33% (3/9) for calcifications, 17% (1/6) for non-mass enhancement, and 0% (0/1) for architectural distortion.

CONCLUSION: Of the radiographic changes prompting an additional biopsy, development of a new mass (38%) and new calcifications (33%) had the highest PPV for invasive progression. Close imaging follow-up should be a critical component for patients undergoing monitoring for DCIS.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Nguyen DL, Shelley Hwang E, Ryser MD, et al. Imaging Changes and Outcomes of Patients Undergoing Active Monitoring for Ductal Carcinoma In Situ: Seven-Year Follow-up Study. Acad Radiol. 2024. PMID: 38184419. doi:10.1016/j.acra.2023.12.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。